quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

Partnerships and hiring data show AI companies are expanding beyond Nvidia chips

View original at cbinsights.com
CB Insights - Enterprise Ai Title: Partnerships and hiring data show AI companies are expanding beyond Nvidia chips Date: 2025-11-04 02:25 Source: https://www.cbinsights.com/research/ai-companies-expand-beyond-nvidia/ <p><a href="https://www.cbinsights.com/company/nvidia">Nvidia</a> isn’t the only AI chip supplier in t…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Google opening TPU capacity at Anthropic scale signals both Anthropic's push for non-Nvidia supply and Google's bet that more buyers want alternatives

    80% confidence
  • Switching from CUDA is a major barrier due to infrastructure, software ecosystem, and unknown learning costs

    80% confidence
  • AI demand is outpacing supply, creating opportunity to develop Trainium chip capacity

    80% confidence
  • As compute comes from multiple vendors, a larger market will emerge for software that abstracts chip differences

    80% confidence
  • More than half of AWS Bedrock service now runs on Trainium AI chips

    80% confidence
  • Early signals in hiring and partnerships show the AI compute mix starting to split away from Nvidia dominance

    80% confidence
  • Anthropic is the notable exception to Nvidia's investments across leading AI companies

    80% confidence
  • TensorWave has deployed North America's largest AMD GPU cluster and is projecting $100M in ARR by year-end

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Partnerships and hiring data show AI companies are expanding beyond Nvidia chips — Source | Via News | pt.VIA.NEWS